Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 |
| Jan 24, 2024 |
| clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT04439006 | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | completed | Phase 1 | 10 | Jennifer WoyachOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02543879 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 94 | Forma Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02782468 | A Study of Pevonedistat in Adult East Asian Participants | completed | Phase 1 | 23 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 3, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05048498 | Pharmacokinetics, Tolerability and Safety of NEX-18a | completed | Phase 1 | 2 | Nanexa ABINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02122081 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 1 | 33 | Sumithira VasuOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04402541 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 55 | Cleave Therapeutics, Inc.INDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT04443751 | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00641030 | Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03746041 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | completed | Phase 1 | 20 | University of RochesterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT00423514 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | completed | Phase 1 / Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | completed | Phase 1 | 21 | Brian JonasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02758223 | Prophylactic Application of Donor-derived TCM After Allogeneic HSCT(PACT) | completed | Phase 1 / Phase 2 | 16 | Wuerzburg University HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03483324 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | completed | Phase 1 | 10 | Angiocrine BioscienceINDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01433965 | Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 16 | University of California, DavisOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02083250 | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | completed | Phase 1 | 12 | Justin Watts, MDOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT00380653 | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes | completed | Phase 1 | 47 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT02464657 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01020539 | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia(AML/MDS/JMML) | completed | Phase 1 | 18 | Columbia UniversityOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT01221857 | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 12 | Gamida Cell ltdINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | completed | Phase 1 | 21 | Jazz PharmaceuticalsINDUSTRY | 2 | Jul 22, 2021 | clinicaltrials |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 45 | Traws Pharma, Inc.INDUSTRY | 2 | Jun 16, 2021 | clinicaltrials |
| NCT03885947 | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | completed | Phase 1 | 7 | Alla KeyznerOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT02485535 | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | completed | Phase 1 | 12 | University of ChicagoOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Mar 19, 2024source: clinicaltrials